Celsion

May 14, 2021

•

Mar 31, 2021

Celsion Q1 2021 Earnings Report

Reported financial results for Q1 2021 and provided a business update, focusing on immuno-oncology and next-generation vaccines.

Key Takeaways

Celsion reported a net loss of $5.7 million, or $0.09 per share, for the first quarter of 2021. The company focused on immuno-oncology and next-generation vaccines, extended its cash operating runway through 2024, and strengthened its balance sheet by raising over $58 million in gross proceeds.

OVATION 2 Study is more than 40% enrolled with 23 clinical sites activated, and enrollment is expected to be completed before the end of 2021.

Announced an initiative to focus on DNA vaccine development leveraging the TheraPlas platform.

Received FDA Fast Track Designation for GEN-1 in Advanced Ovarian Cancer.

Filed a provisional U.S. patent application for a novel DNA-based vaccine for preventing or treating infections from a broad range of infectious agents.